Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
LEXINGTON, Mass., February 15, 2023--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata.
Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.
By Davit Kirakosyan
If all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Market Intelligence. The two companies didn't hesitate to point out that this is roughly 33% higher than the latter's 30-day-trailing weighted average share price as of Wednesday, Jan. 18.
We can readily understand why investors are attracted to unprofitable companies. Indeed, Concert Pharmaceuticals...
An Indian drugmaker will buy Lexington's Concert Pharmaceuticals (NASDAQ: CNCE) in a cash deal valued at an initial $576 million, the two companies announced Thursday.
Sun Pharmaceutical Industries Limited, India's top pharmaceutical company, has agreed to acquire Concert Pharmaceuticals Inc (NASDAQ: CNCE) for an upfront payment of $8.00 per share, or $576 million in equity value. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods. Concert is a late-stage biotechno
Sun Pharmaceutical Industries Limited , India's largest drugmaker, said on Thursday it will acquire U.S.-based Concert Pharmaceuticals for $576 million in cash to gain access to its experimental drug for treating patchy baldness. The deal is the Indian drugmaker's biggest since its $3.2 billion acquisition of generic drugmaker Ranbaxy Laboratories Ltd in 2014, according to Refinitiv data. Sun Pharma offered Concert $8 per share, representing a premium of 16% to the stock's last close.
MUMBAI & LEXINGTON, Mass., January 19, 2023--Sun Pharma to acquire Concert Pharmaceuticals.
Concert (CNCE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.